gp13 (EHV-gC): a complement receptor induced by equine herpesviruses

Hartwig P. Huemer, Norbert Nowotny, Brendan S. Crabb, Hermann Meyer, Peter H. Hübert

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Equine herpesviruses type 1 (EHV-1) and type 4 (EHV-4) induce a complement receptor protein on the surface of infected cells capable of binding to the third component of complement (C3). The protein mediating the binding to the C3 component of complement was identified as glycoprotein 13 (gp13, EHV-gC), as expression of the cloned viral gene under the control of a CMV promoter induced C3 binding activity at the transfected cell surface. Comparable to glycoprotein C (gC) from herpes simplex virus type 1 (HSV-1-gC), glycoprotein III from pseudorabiesvirus (gIII, PRV-gC) and bovine herpesvirus-1 (gIII, BHV-1-gC), gp13 derived from EHV-infected cell lysates bound to C3 fixed to solid phase, showing preferential binding to the appropriate host complement component. Similar to wild-type isolates, a highly attenuated vaccine EHV-1 strain also displayed complement receptor activity despite apparent differences of the gp13 gene in restriction enzyme digest pattern and reactivity with monoclonal antibodies. In addition, other structural proteins were altered in the vaccine strain as compared to wild-type strains, which might contribute to its attenuated phenotype. In contrast to the situation observed with HSV-1-gC, the interaction of gp13 (EHV-gC) with horse complement was not inhibited by polyanionic substances like heparin or dextran sulfate. These results suggest structural differences in the particular binding mechanism of the respective viral envelope proteins.

Original languageEnglish
Pages (from-to)113-126
Number of pages14
JournalVirus Research
Volume37
Issue number2
DOIs
Publication statusPublished - 1995

Fingerprint

Complement Receptors
Herpesviridae
Horses
Human Herpesvirus 1
Equid Herpesvirus 1
Complement C3
Glycoproteins
Equid Herpesvirus 4
Bovine Herpesvirus 1
Viral Envelope Proteins
Attenuated Vaccines
Dextran Sulfate
Viral Genes
Protein Binding
Heparin
glycoprotein gC, herpes simplex virus type 1
Complement System Proteins
Vaccines
Monoclonal Antibodies
Phenotype

Keywords

  • Complement receptor
  • Equine herpesvirus (EHV)
  • Glycoprotein
  • gp13
  • Heparin

ASJC Scopus subject areas

  • Cancer Research
  • Virology
  • Infectious Diseases
  • Molecular Biology

Cite this

gp13 (EHV-gC) : a complement receptor induced by equine herpesviruses. / Huemer, Hartwig P.; Nowotny, Norbert; Crabb, Brendan S.; Meyer, Hermann; Hübert, Peter H.

In: Virus Research, Vol. 37, No. 2, 1995, p. 113-126.

Research output: Contribution to journalArticle

Huemer, Hartwig P. ; Nowotny, Norbert ; Crabb, Brendan S. ; Meyer, Hermann ; Hübert, Peter H. / gp13 (EHV-gC) : a complement receptor induced by equine herpesviruses. In: Virus Research. 1995 ; Vol. 37, No. 2. pp. 113-126.
@article{ec7a8b0fa8ff4914a7c73ad97e48bed6,
title = "gp13 (EHV-gC): a complement receptor induced by equine herpesviruses",
abstract = "Equine herpesviruses type 1 (EHV-1) and type 4 (EHV-4) induce a complement receptor protein on the surface of infected cells capable of binding to the third component of complement (C3). The protein mediating the binding to the C3 component of complement was identified as glycoprotein 13 (gp13, EHV-gC), as expression of the cloned viral gene under the control of a CMV promoter induced C3 binding activity at the transfected cell surface. Comparable to glycoprotein C (gC) from herpes simplex virus type 1 (HSV-1-gC), glycoprotein III from pseudorabiesvirus (gIII, PRV-gC) and bovine herpesvirus-1 (gIII, BHV-1-gC), gp13 derived from EHV-infected cell lysates bound to C3 fixed to solid phase, showing preferential binding to the appropriate host complement component. Similar to wild-type isolates, a highly attenuated vaccine EHV-1 strain also displayed complement receptor activity despite apparent differences of the gp13 gene in restriction enzyme digest pattern and reactivity with monoclonal antibodies. In addition, other structural proteins were altered in the vaccine strain as compared to wild-type strains, which might contribute to its attenuated phenotype. In contrast to the situation observed with HSV-1-gC, the interaction of gp13 (EHV-gC) with horse complement was not inhibited by polyanionic substances like heparin or dextran sulfate. These results suggest structural differences in the particular binding mechanism of the respective viral envelope proteins.",
keywords = "Complement receptor, Equine herpesvirus (EHV), Glycoprotein, gp13, Heparin",
author = "Huemer, {Hartwig P.} and Norbert Nowotny and Crabb, {Brendan S.} and Hermann Meyer and H{\"u}bert, {Peter H.}",
year = "1995",
doi = "10.1016/0168-1702(95)00027-N",
language = "English",
volume = "37",
pages = "113--126",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - gp13 (EHV-gC)

T2 - a complement receptor induced by equine herpesviruses

AU - Huemer, Hartwig P.

AU - Nowotny, Norbert

AU - Crabb, Brendan S.

AU - Meyer, Hermann

AU - Hübert, Peter H.

PY - 1995

Y1 - 1995

N2 - Equine herpesviruses type 1 (EHV-1) and type 4 (EHV-4) induce a complement receptor protein on the surface of infected cells capable of binding to the third component of complement (C3). The protein mediating the binding to the C3 component of complement was identified as glycoprotein 13 (gp13, EHV-gC), as expression of the cloned viral gene under the control of a CMV promoter induced C3 binding activity at the transfected cell surface. Comparable to glycoprotein C (gC) from herpes simplex virus type 1 (HSV-1-gC), glycoprotein III from pseudorabiesvirus (gIII, PRV-gC) and bovine herpesvirus-1 (gIII, BHV-1-gC), gp13 derived from EHV-infected cell lysates bound to C3 fixed to solid phase, showing preferential binding to the appropriate host complement component. Similar to wild-type isolates, a highly attenuated vaccine EHV-1 strain also displayed complement receptor activity despite apparent differences of the gp13 gene in restriction enzyme digest pattern and reactivity with monoclonal antibodies. In addition, other structural proteins were altered in the vaccine strain as compared to wild-type strains, which might contribute to its attenuated phenotype. In contrast to the situation observed with HSV-1-gC, the interaction of gp13 (EHV-gC) with horse complement was not inhibited by polyanionic substances like heparin or dextran sulfate. These results suggest structural differences in the particular binding mechanism of the respective viral envelope proteins.

AB - Equine herpesviruses type 1 (EHV-1) and type 4 (EHV-4) induce a complement receptor protein on the surface of infected cells capable of binding to the third component of complement (C3). The protein mediating the binding to the C3 component of complement was identified as glycoprotein 13 (gp13, EHV-gC), as expression of the cloned viral gene under the control of a CMV promoter induced C3 binding activity at the transfected cell surface. Comparable to glycoprotein C (gC) from herpes simplex virus type 1 (HSV-1-gC), glycoprotein III from pseudorabiesvirus (gIII, PRV-gC) and bovine herpesvirus-1 (gIII, BHV-1-gC), gp13 derived from EHV-infected cell lysates bound to C3 fixed to solid phase, showing preferential binding to the appropriate host complement component. Similar to wild-type isolates, a highly attenuated vaccine EHV-1 strain also displayed complement receptor activity despite apparent differences of the gp13 gene in restriction enzyme digest pattern and reactivity with monoclonal antibodies. In addition, other structural proteins were altered in the vaccine strain as compared to wild-type strains, which might contribute to its attenuated phenotype. In contrast to the situation observed with HSV-1-gC, the interaction of gp13 (EHV-gC) with horse complement was not inhibited by polyanionic substances like heparin or dextran sulfate. These results suggest structural differences in the particular binding mechanism of the respective viral envelope proteins.

KW - Complement receptor

KW - Equine herpesvirus (EHV)

KW - Glycoprotein

KW - gp13

KW - Heparin

UR - http://www.scopus.com/inward/record.url?scp=0028979932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028979932&partnerID=8YFLogxK

U2 - 10.1016/0168-1702(95)00027-N

DO - 10.1016/0168-1702(95)00027-N

M3 - Article

C2 - 7483825

AN - SCOPUS:0028979932

VL - 37

SP - 113

EP - 126

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 2

ER -